{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:39:41Z","timestamp":1787582381386,"version":"build-2736575974"},"update-to":[{"DOI":"10.1002\/14651858.cd004197.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,4,25]],"date-time":"2017-04-25T00:00:00Z","timestamp":1493078400000}}],"reference-count":275,"publisher":"Wiley","issue":"2","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd004197.pub5","type":"journal-article","created":{"date-parts":[[2017,4,25]],"date-time":"2017-04-25T15:20:54Z","timestamp":1493133654000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis"],"prefix":"10.1002","volume":"2020","author":[{"given":"Simon C","family":"Langton Hewer","sequence":"first","affiliation":[{"name":"Bristol Royal Hospital for Children; Paediatric Respiratory Medicine; Upper Maudlin Street Bristol Avon UK BS2 8BJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan R","family":"Smyth","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Nottingham; Division of Child Health, Obstetrics & Gynaecology (COG); Queens Medical Centre Derby Road Nottingham UK NG7 2UH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,4,25]]},"reference":[{"key":"10.1002\/14651858.CD004197.pub5-BIB0001|cit1","first-page":"300","article-title":"A randomized, controlled trial of inhaled tobramycin in young children with cystic fibrosis: Eradication of pseudomonas from the lower airway","volume":"Suppl 24","author":"Gibson","year":"2002","journal-title":"Pediatric Pulmonology"},{"issue":"6","key":"10.1002\/14651858.CD004197.pub5-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"841 Online","DOI":"10.1164\/rccm.200208-855OC","article-title":"Online Supplement to 'Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis'. [online]","volume":"167","author":"Gibson","year":"2003","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"6","key":"10.1002\/14651858.CD004197.pub5-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1164\/rccm.200208-855OC","article-title":"Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis","volume":"167","author":"Gibson","year":"2003","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0005|cit4","first-page":"106","article-title":"Serum and lower respiratory tract tobramycin concentrations produced by inhaled tobramycin (TOBI) in young children with cystic fibrosis","volume":"Suppl 19","author":"Rosenfeld","year":"1999","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0004|cit5","first-page":"262","article-title":"Serum pharmacokinetics and safety of inhaled tobramycin in very young CF patients","volume":"Suppl 19","author":"Rosenfeld","year":"1999","journal-title":"Pediatric Pulmonology"},{"issue":"S2","key":"10.1002\/14651858.CD004197.pub5-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1016\/S1569-1993(08)60246-5","article-title":"Eradication of recent Pseudomonas aeruginosa isolation: TOBI versus colistin\/ciprofloxacin","volume":"7","author":"Proesmans","year":"2008","journal-title":"Journal of Cystic Fibrosis"},{"issue":"S32","key":"10.1002\/14651858.CD004197.pub5-BIB0007|cit7","first-page":"321","article-title":"Eradication of recent Pseudomonas aeruginosa isolation: TOBI versus colistin\/ciprofloxacin","volume":"44","author":"Proesmans","year":"2009","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/S1569-1993(11)60119-7","article-title":"Eradication of recent pseudomonas aeruginosa infection: TOBI versus Colistineb\u00ae\/ ciprofloxacin","volume":"10 Suppl 1","author":"Proesmans","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"issue":"1","key":"10.1002\/14651858.CD004197.pub5-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jcf.2012.06.001","article-title":"Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis","volume":"12","author":"Proesmans","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"issue":"S29","key":"10.1002\/14651858.CD004197.pub5-BIB0010|cit10","first-page":"318","article-title":"Inhaled tobramycin nebuliser solution for treatment of early Pseudomonas aeruginosa infection: first results from the Elite study","volume":"41","author":"Ratjen","year":"2006","journal-title":"Pediatric Pulmonlogy"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S1569-1993(06)80085-8","article-title":"Safety of inhaled tobramycin nebuliser solution for treatment of early pseudomonas aeruginosa infection: first results from the ELITE study","volume":"5 Suppl 1","author":"Ratjen","year":"2006","journal-title":"Journal of Cystic Fibrosis"},{"issue":"S31","key":"10.1002\/14651858.CD004197.pub5-BIB0013|cit12","first-page":"319","article-title":"Short and long-term efficacy of inhaled tobramycin in early P. Aeruginosa infection: the ELITE study","volume":"43","author":"Ratjen","year":"2008","journal-title":"Pediatric Pulmonology"},{"issue":"4","key":"10.1002\/14651858.CD004197.pub5-BIB0012|cit13","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1136\/thx.2009.121657","article-title":"Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial","volume":"65","author":"Ratjen","year":"2010","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/S1569-1993(08)60098-3","article-title":"Inhaled tobramycin nebulizer solution for treatment of early Pseudomonas aeruginosa infection; the ELITE study","volume":"7 Suppl 2","author":"Ratjen","year":"2008","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0015|cit15","first-page":"348","article-title":"Semi-automated rep-pcr genotyping of pseudomonas aeruginosa in Italian CF patients in eradication therapy","volume":"45 Suppl 33","author":"Cariani","year":"2010","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0016|cit16","first-page":"288","article-title":"Anti-P.aeruginosa antibodies and microbiological outcome in patients treated with early eradication therapy","volume":"48 Suppl 36","author":"Dolce","year":"2013","journal-title":"Pediatric Pulmonology"},{"issue":"S33","key":"10.1002\/14651858.CD004197.pub5-BIB0017|cit17","first-page":"337","article-title":"Pseudomonas aeruginosa eradication in cystic fibrosis: preliminary data from a randomized multicenter study of two different early antibiotic treatment protocols","volume":"45","author":"Taccetti","year":"2010","journal-title":"Pediatric Pulmonology"},{"issue":"S34","key":"10.1002\/14651858.CD004197.pub5-BIB0018|cit18","first-page":"317","article-title":"Pseudomonas aeruginosa microbiological status and emergence of other pathogens after early eradication treatment in cystic fibrosis: a post-trial follow-up","volume":"46","author":"Taccetti","year":"2011","journal-title":"Pediatric Pulmonology"},{"issue":"S32","key":"10.1002\/14651858.CD004197.pub5-BIB0019|cit19","first-page":"354","article-title":"Early antibiotic treatment for Pseudomonas aeruginosa eradication in cystic fibrosis patients: a randomized multicenter study of two different protocols","volume":"44","author":"Taccetti","year":"2009","journal-title":"Pediatric Pulmonology"},{"issue":"S34","key":"10.1002\/14651858.CD004197.pub5-BIB0020|cit20","first-page":"317","article-title":"Pseudomonas aeruginosa eradication in cystic fibrosis: final results of a randomized multicenter study of two different early antibiotic treatment protocols","volume":"46","author":"Taccetti","year":"2011","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0021|cit21","first-page":"328","article-title":"Is early eradication treatment against P.aeruginosa associated with the emergence of other non-fermenter gram negatives","volume":"48 Suppl 36","author":"Taccetti","year":"2013","journal-title":"Pediatric Pulmonology"},{"issue":"10","key":"10.1002\/14651858.CD004197.pub5-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1136\/thoraxjnl-2011-200832","article-title":"Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with\u00a0cystic\u00a0fibrosis: a randomised multicentre study comparing two different protocols","volume":"67","author":"Taccetti\u00a0G","year":"2012","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/S1569-1993(10)60111-7","article-title":"Epidemiology of first\/new Pseudomonas aeruginosa infection in cystic fibrosis patients","volume":"9 Suppl 1","author":"Zavataro","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"issue":"2","key":"10.1002\/14651858.CD004197.pub5-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jcf.2012.08.001","article-title":"Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial","volume":"12","author":"Anstead","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"issue":"S34","key":"10.1002\/14651858.CD004197.pub5-BIB0025|cit25","first-page":"303","article-title":"Pseudomonas aeruginosa serology predicts response to treatment and re-infection in the EPIC clinical study","volume":"46","author":"Anstead","year":"2011","journal-title":"Pediatric Pulmonology"},{"issue":"S32","key":"10.1002\/14651858.CD004197.pub5-BIB0026|cit26","first-page":"183","article-title":"Safety and efficacy of anti-pseudomonal therapy for early eradication of Pseudomonas aeruginosa: the EPIC study","volume":"44","author":"Hamblett","year":"2009","journal-title":"Pediatric Pulmonology"},{"issue":"S35","key":"10.1002\/14651858.CD004197.pub5-BIB0027|cit27","first-page":"317","article-title":"Pseudomonas aeruginosa (PA) phenotypes associated with persistent early infection in CF patients in the EPIC Clinical Trial","volume":"47","author":"Hoffman","year":"2012","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0028|cit28","first-page":"349","article-title":"Studies on the effects of ciprofloxacin on pseudomonas aeruginosa evolution in cystic fibrosis patients","volume":"49","author":"Jorth","year":"2014","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0029|cit29","first-page":"304, Abstract n","article-title":"Early evolution of pseudomonas aeruginosa during cystic fibrosis infection [abstract]","volume":"50 Suppl 41","author":"Jorth","year":"2015","journal-title":"Pediatric Pulmonology"},{"issue":"S33","key":"10.1002\/14651858.CD004197.pub5-BIB0030|cit30","first-page":"335","article-title":"Association between baseline pseudomonas aeruginosa positivity in EPIC clinical trial participants & prior antibiotic exposure","volume":"45","author":"Khan","year":"2010","journal-title":"Pediatric Pulmonology"},{"issue":"5","key":"10.1002\/14651858.CD004197.pub5-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/cid\/civ377","article-title":"Impact of Sustained Eradication of New Pseudomonas aeruginosa Infection on Long-term Outcomes in Cystic Fibrosis","volume":"61","author":"Mayer-Hamblett","year":"2015","journal-title":"Clinical Infectious Diseases"},{"issue":"2","key":"10.1002\/14651858.CD004197.pub5-BIB0032|cit32","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/ppul.21525","article-title":"Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis","volume":"47","author":"Mayer-Hamblett","year":"2012","journal-title":"Pediatric Pulmonology"},{"issue":"10","key":"10.1002\/14651858.CD004197.pub5-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/ppul.22693","article-title":"Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosis","volume":"48","author":"Mayer-Hamblett","year":"2013","journal-title":"Pediatric Pulmonology"},{"issue":"S28","key":"10.1002\/14651858.CD004197.pub5-BIB0034|cit34","first-page":"146","article-title":"TOBI use in infants and children with early Pseudomonas Aeruginosa infection - duration of effect and epic update","volume":"40","author":"Ramsey","year":"2005","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1016\/S1569-1993(10)60210-X","article-title":"Comparative efficacy and safety of four randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis","volume":"9 Suppl 1","author":"Treggiari","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"issue":"S32","key":"10.1002\/14651858.CD004197.pub5-BIB0036|cit36","first-page":"316, Abstract n","article-title":"Early anti-pseudomonal infection in children with CF: study population and conduct of the \"EPIC\" clinical trial [abstract]","volume":"44","author":"Treggiari","year":"2009","journal-title":"Pediatric Pulmonology"},{"issue":"9","key":"10.1002\/14651858.CD004197.pub5-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1001\/archpediatrics.2011.136","article-title":"Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis","volume":"165","author":"Treggiari","year":"2011","journal-title":"Archives of Pediatrics and Adolescent Medicine"},{"issue":"3","key":"10.1002\/14651858.CD004197.pub5-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.cct.2009.01.003","article-title":"Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study","volume":"30","author":"Treggiari","year":"2009","journal-title":"Contempory Clinical Trials"},{"issue":"8769","key":"10.1002\/14651858.CD004197.pub5-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/0140-6736(91)91446-2","article-title":"Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment","volume":"338","author":"Valerius","year":"1991","journal-title":"Lancet"},{"issue":"Supplement S5","key":"10.1002\/14651858.CD004197.pub5-BIB0040|cit40","first-page":"248","article-title":"Prevention of chronic colonization with Pseudomonas aeruginosa in patients with CF by early treatment with ciprofloxacin and colistin aerosol inhalations","volume":"9","author":"Valerius","year":"1990","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0041|cit41","first-page":"250","article-title":"Prevention of chronic pseudomonas aeruginosa infection by early inhalation therapy with tobramycin","volume":"Suppl 10","author":"Ratjen","year":"1994","journal-title":"Pediatric Pulmonology"},{"issue":"2","key":"10.1002\/14651858.CD004197.pub5-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/(SICI)1099-0496(199802)25:2<88::AID-PPUL3>3.0.CO;2-J","article-title":"Placebo-controlled, double-blind, randomised study of aerosolised tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis","volume":"25","author":"Wiesemann","year":"1998","journal-title":"Pediatric Pulmonology"},{"issue":"3","key":"10.1002\/14651858.CD004197.pub5-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1378\/chest.122.3.930","article-title":"Evaluation of bronchial constriction in children with cystic fibrosis after inhaling two different preparations of tobramycin","volume":"122","author":"Alothman","year":"2002","journal-title":"Chest"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0044|cit44","first-page":"298","article-title":"In cystic fibrosis (CF) patients, does the inhalation of an intravenous tobramycin preparation result in more bronchospasm than a preservative free tobramycin preparation?","volume":"Suppl 20","author":"Alothman","year":"2000","journal-title":"Pediatric Pulmonology"},{"issue":"2","key":"10.1002\/14651858.CD004197.pub5-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1378\/chest.127.2.522","article-title":"Bronchial constriction and inhaled colistin in cystic fibrosis","volume":"127","author":"Alothman","year":"2005","journal-title":"Chest"},{"issue":"9","key":"10.1002\/14651858.CD004197.pub5-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1136\/thx.53.9.732","article-title":"Long term follow up of changes in FEV1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis","volume":"53","author":"Ballman","year":"1998","journal-title":"Thorax"},{"issue":"9","key":"10.1002\/14651858.CD004197.pub5-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1136\/adc.67.9.1086","article-title":"The value of serum IgG titres against Pseudomonas aeruginosa in the management of early infection in cystic fibrosis","volume":"67","author":"Brett","year":"1992","journal-title":"Archives of Disease in Childhood"},{"issue":"1","key":"10.1002\/14651858.CD004197.pub5-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00006454-199701000-00031","article-title":"Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime\/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group","volume":"16","author":"Church","year":"1997","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"9","key":"10.1002\/14651858.CD004197.pub5-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"818-25 online","DOI":"10.1136\/thoraxjnl-2012-202230","article-title":"Online supplementary data to \"Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection\" [online","volume":"68","author":"Clancy","year":"2013","journal-title":"Thorax"},{"issue":"9","key":"10.1002\/14651858.CD004197.pub5-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/thoraxjnl-2012-202230","article-title":"Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection","volume":"68","author":"Clancy","year":"2013","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0051|cit51","first-page":"299","article-title":"Full analysis of data from two phase II blinded & placebo-controlled studies of nebulized liposomal amikacin for inhalation (Arikace) in the treatment of CF patients with pseudomonas aeruginosa lung infection","volume":"45 Suppl 33","author":"Clancy","year":"2010","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/S1569-1993(08)60099-5","article-title":"A randomised placebo-controlled study of nebulized liposomal amikacin (Arikace) in the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection","volume":"7 Suppl 2","author":"Dupont","year":"2008","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0053|cit53","first-page":"301","article-title":"A randomized placebo-controlled study of nebulized liposomal amikacin (Arikace) in the treatment of cystic fibrosis patients with chronic Pseudomonas Aeruginosa lung infection","volume":"43 Suppl 31","author":"Dupont","year":"2008","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0054|cit54","article-title":"A randomized placebo-controlled study of nebulized liposomal amikacin (Arikace) in the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection (protocol TR02-105)","volume":"179","author":"Gupta","year":"2009","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"4","key":"10.1002\/14651858.CD004197.pub5-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ppul.21376","article-title":"Higher tobramycin concentration and vibrating mesh technology can shorten antibiotic treatment time in cystic fibrosis","volume":"46","author":"Coates","year":"2011","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1016\/S1569-1993(09)60261-7","article-title":"Lung delivery of a new tobramycin nebuliser solution (150mg\/1.5ml) by an investigational eFlow\u00ae nebuliser is equivalent to TOBI\u00ae but in a fraction of time","volume":"8 Suppl 2","author":"Denk","year":"2009","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S1569-1993(10)60085-9","article-title":"In-vivo data support equivalent therapeutic efficacy of a new tobramycin inhalation solution (150mg\/1.5ml) administered by the eFlow\u00ae electronic nebuliser compared to TOBI\u00ae in the PARI LC PLUS\u00ae","volume":"9 Suppl 1","author":"Keller","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"issue":"5","key":"10.1002\/14651858.CD004197.pub5-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jcf.2016.01.005","article-title":"Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026)treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection","volume":"15","author":"Elborn","year":"2016","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/S1569-1993(14)60050-3","article-title":"Prolonged improvement in lung function and quality of life in cystic fibrosis: a 24-week extension study of levofloxacin nebulization solution (APT-1026) versus tobramycin nebulization solution in stable CF patients with chronic pseudomonas aeruginosa infection","volume":"13 Suppl 2","author":"Elborn","year":"2014","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/S1569-1993(13)60108-3","article-title":"Phase 3 trial of inhaled levofloxacin (Aeruquin\u00e2\u2122, MP-376, APT-1026) vs. tobramycin inhalation solution (TIS) in intensively treated CF patients over 6 months","volume":"12 Suppl 1","author":"Elborn","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"issue":"4","key":"10.1002\/14651858.CD004197.pub5-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jcf.2014.12.013","article-title":"A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients","volume":"14","author":"Elborn","year":"2015","journal-title":"Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society"},{"issue":"4","key":"10.1002\/14651858.CD004197.pub5-BIB0062|cit62","first-page":"507-14. Online","article-title":"A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients","volume":"14","author":"Elborn","year":"2015","journal-title":"Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0063|cit63","first-page":"359","article-title":"Pulmonary exacerbations and changes in lung function in CF adults with P. aeruginosa treated with inhaled levofloxacin (Quinsair\u00ae) or tobramycin","volume":"51 Suppl 45","author":"Fischer","year":"2016","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0066|cit64","unstructured":"Flume P Trial of aeroquin versus tobramycin inhalation solution (TIS) in cystic fibrosis (CF) patients (www.clinicaltrials.gov) (accessed 21 Oct 2014) 2014"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0064|cit65","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1016\/S1569-1993(16)30278-8","article-title":"History of pulmonary exacerbations (PEx) as a predictor of response to nebulized levofloxacin compared with nebulized tobramycin","volume":"2015 Suppl 1","author":"Flume","year":"2016","journal-title":"Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0065|cit66","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/S1569-1993(15)30294-0","article-title":"Safety profile of levofloxacin inhalation solution from 3 controlled cystic fibrosis trials [abstract]","volume":"14 Suppl 1","author":"Flume","year":"2015","journal-title":"Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0067|cit67","first-page":"356","article-title":"How often is pulmonary exacerbation defined by \u22654 Fuchs criteria associated with antibiotic treatment?","volume":"49 Suppl 38","author":"Devanter","year":"2014","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0068|cit68","first-page":"352","article-title":"Aztreonam for inhalation solution (AZLI) and tobramycin inhalation solution (TIS) continuous alternating therapy (CAT) for cystic fibrosis (CF) patients with chronic pseudomonas aeruginosa (PA) infection: a randomized, double-blind, placebo-controlled trial","volume":"50 Suppl 41","author":"Flume","year":"2015","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0070|cit69","unstructured":"Flume P A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of MP-376 (Levofloxacin Inhalation Solution; Aeroquin\u2122) In Stable Cystic Fibrosis Patients www.clinicaltrials.gov (accessed 21 Oct 2014) 2014"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0069|cit70","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/S1569-1993(15)30294-0","article-title":"Safety profile of levofloxacin inhalation solution from 3 controlled cystic fibrosis trials","volume":"14 Suppl 1","author":"Flume","year":"2015","journal-title":"Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society"},{"issue":"4","key":"10.1002\/14651858.CD004197.pub5-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jcf.2015.12.004","article-title":"A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients","volume":"15","author":"Flume","year":"2016","journal-title":"Journal of Cystic Fibrosis"},{"issue":"4","key":"10.1002\/14651858.CD004197.pub5-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"495-502. Online","DOI":"10.1016\/j.jcf.2015.12.004","article-title":"A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients","volume":"15","author":"Flume","year":"2016","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0073|cit73","first-page":"356","article-title":"How often is pulmonary exacerbation defined by \u22654 Fuchs criteria associated with antibiotic treatment?","volume":"49 Suppl 38","author":"Devanter","year":"2014","journal-title":"Pediatric Pulmonlogy"},{"issue":"5","key":"10.1002\/14651858.CD004197.pub5-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/(SICI)1099-0496(199705)23:5<330::AID-PPUL4>3.0.CO;2-O","article-title":"Antibiotic treatment of initial colonisation with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis","volume":"23","author":"Frederiksen","year":"1997","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl 27","key":"10.1002\/14651858.CD004197.pub5-BIB0075|cit75","first-page":"250","article-title":"A phase 1 study to assess the tolerability of a novel tobramycin powder for inhalation (TPI) formulation in cystic fibrosis subjects","volume":"38","author":"Geller","year":"2004","journal-title":"Pediatric Pulmonology"},{"issue":"4","key":"10.1002\/14651858.CD004197.pub5-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/ppul.20594","article-title":"Novel tobramycin inhalation powder in cystic fibrosis subjects: Pharmacokinetics and safety","volume":"42","author":"Geller","year":"2007","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0077|cit77","first-page":"250","article-title":"Single dose pharmacokinetics of tobramycin after administration of a novel dry powder formulation (TPI) in subjects with cystic fibrosis (cf)","volume":"38 Suppl 27","author":"Rodriguez","year":"2004","journal-title":"Pediatric Pulmonology"},{"issue":"Meeting Abstrac","key":"10.1002\/14651858.CD004197.pub5-BIB0078|cit78","article-title":"Phase 2b study of inhaled MP-376 (Aeroquin, levofloxacin inhalation solution) in stable cystic fibrosis (CF) patients with chronic Pseudomonas Aeruginosa (PA) lung infection","volume":"181","author":"Conrad","year":"2010","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/S1569-1993(10)60087-2","article-title":"Effects of inhaled MP-376 (aeroquin, levofloxacin inhalation solution) on lung function in stable cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa (PA) lung infection","volume":"9 Suppl 1","author":"Flume","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/S1569-1993(15)30294-0","article-title":"Safety profile of levofloxacin inhalation solution from 3 controlled cystic fibrosis trials","volume":"14 Suppl 1","author":"Flume","year":"2015","journal-title":"Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S1569-1993(11)60105-7","article-title":"Effects of inhaled MP-376 (Aeroquin\u00e2\u201e\u00a2 levofloxacin inhalation solution) on cystic fibrosis patients with both Staphylococcus aureus (SA) and Pseudomonas aeruginosa (PA) lung infection","volume":"10 Suppl 1","author":"Flume","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"issue":"11","key":"10.1002\/14651858.CD004197.pub5-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1164\/rccm.201008-1293OC","article-title":"Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa","volume":"183","author":"Geller","year":"2011","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"11","key":"10.1002\/14651858.CD004197.pub5-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"1510-1516 onlin","DOI":"10.1164\/rccm.201008-1293OC","article-title":"Online supplemental methods to \"Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa\" [online]","volume":"183","author":"Geller","year":"2011","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0084|cit84","first-page":"301","article-title":"Effects of inhaled MP-376 (aeroquin, levofloxacin inhalation solution) on the need for other anti-pseudomonal antimicrobials in stable CF patients with chronic pseudomonas aeruginosa lung infection","volume":"45 Suppl 33","author":"Geller","year":"2010","journal-title":"Pediatric Pulmonology"},{"issue":"7","key":"10.1002\/14651858.CD004197.pub5-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/ppul.20625","article-title":"Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis","volume":"42","author":"Gibson","year":"2007","journal-title":"Pediatric Pulmonology"},{"issue":"9","key":"10.1002\/14651858.CD004197.pub5-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"818-25 online","DOI":"10.1136\/thoraxjnl-2012-202230","article-title":"Online supplementary data to \"Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection\" [online","volume":"68","author":"Clancy","year":"2013","journal-title":"Thorax"},{"issue":"9","key":"10.1002\/14651858.CD004197.pub5-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/thoraxjnl-2012-202230","article-title":"Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection","volume":"68","author":"Clancy","year":"2013","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0088|cit88","first-page":"299","article-title":"Full analysis of data from two phase II blinded & placebo-controlled studies of nebulized liposomal amikacin for inhalation (Arikace) in the treatment of CF patients with Pseudomonas aeruginosa lung infection","volume":"45 Suppl 33","author":"Clancy","year":"2010","journal-title":"Pediatric Pulmonology"},{"issue":"Meeting abstrac","key":"10.1002\/14651858.CD004197.pub5-BIB0089|cit89","article-title":"Evaluation of two phase II blinded and placebo-controlled studies of nebulized liposomal amikacin (Arikace\") in the treatment of cystic fibrosis patients with Pseudomonas aeruginosa lung infection","volume":"181","author":"Dupont","year":"2010","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"S32","key":"10.1002\/14651858.CD004197.pub5-BIB0090|cit90","first-page":"295","article-title":"A phase 2 blinded and placebo-controlled study of nebulized liposomal amikacin (arikace) in the treatment of CF patients with Pseudomonas aeruginosa lung infection","volume":"44","author":"Goss","year":"2009","journal-title":"Pediatric Pulmonology"},{"issue":"2","key":"10.1002\/14651858.CD004197.pub5-BIB0091|cit91","first-page":"79","article-title":"Eradication of initial Pseudomonas aeruginosa colonisation in patients with cystic fibrosis","volume":"7","author":"Griese","year":"2002","journal-title":"European Journal of Medical Research"},{"issue":"1","key":"10.1002\/14651858.CD004197.pub5-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/ppul.10019","article-title":"Effects of inhaled gentamicin prophylaxis on acquisition of Pseudomonas aeruginosa in children with cystic fibrosis: a pilot study","volume":"33","author":"Heinzl","year":"2002","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/S1569-1993(09)60158-2","article-title":"Eradication of Pseudomonas aeruginosa in adults with CF","volume":"8 Suppl 2","author":"Kenny","year":"2009","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"e000021","DOI":"10.1136\/bmjresp-2014-000021","article-title":"Eradication of Pseudomonas aeruginosa in adults with cystic fibrosis","volume":"1","author":"Kenny","year":"2014","journal-title":"BMJ Open Respiratory Research"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0095|cit95","article-title":"Tobramycin inhalation powder is effective and safe in the treatment of chronic pulmonary Pseudomonas aeruginosa (Pa) infection in patients with cystic fibrosis","volume":"179","author":"Konstan","year":"2009","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/S1569-1993(09)60109-0","article-title":"Effective treatment of chronic Pseudomonas aeruginosa (Pa) infection with tobramycin inhalation powder in CF patients","volume":"8 Suppl 2","author":"Konstan","year":"2009","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/ppul.21356","article-title":"Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: The EVOLVE trial","volume":"46","author":"Konstan","year":"2010","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0098|cit98","first-page":"344","article-title":"Safety of inhaled tobramycin in patients with cystic fibrosis","volume":"46 Suppl 34","author":"McColley","year":"2011","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0099|cit99","unstructured":"Novartis (NCT00125346) Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Subjects (EVOLVE) Http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00125346 2010"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/S1569-1993(14)60179-X","article-title":"Tobramycin powder for inhalation is effective in advanced stage CF lung disease: the EAGER trial","volume":"13 Suppl 2","author":"Chiron","year":"2014","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S1569-1993(10)60084-7","article-title":"Treatment convenience and satisfaction of tobramycin inhalation powder (TIP) versus TOBI in cystic fibrosis (CF) patients","volume":"9 Suppl 1","author":"Geller","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S1569-1993(11)60100-8","article-title":"Microbiological and clinical response to tobramycin inhalation powder (TIP\u00e2\u201e\u00a2) in cystic fibrosis patients with chronic Pseudomonas aeruginosa (Pa) infection [abstract]","volume":"10 Suppl 1","author":"Geller","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"issue":"3","key":"10.1002\/14651858.CD004197.pub5-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"388","DOI":"10.4187\/respcare.02264","article-title":"Tobramycin inhalation powder in cystic fibrosis patients: response by age group","volume":"59","author":"Geller","year":"2014","journal-title":"Respiratory Care"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S1569-1993(10)60083-5","article-title":"Safety and efficacy of tobramycin inhalation powder (TIP) in treating CF patients infected with Pseudomonas aeruginosa (Pa)","volume":"9 Suppl 1","author":"Konstan","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0105|cit105","first-page":"303","article-title":"Tobramycin inhalation powder (TIP) versus tobramycin inhalation solution (TOBI\u00ae): the EAGER trial","volume":"45 Suppl 33","author":"Konstan","year":"2010","journal-title":"Pediatric Pulmonology"},{"issue":"1","key":"10.1002\/14651858.CD004197.pub5-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jcf.2010.10.003","article-title":"Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial","volume":"10","author":"Konstan","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0107|cit107","first-page":"344","article-title":"Safety of inhaled tobramycin in patients with cystic fibrosis","volume":"46 Suppl 34","author":"McColley","year":"2011","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0108|cit108","first-page":"283","article-title":"Reduced administration time for inhaled tobramycin in cystic fibrosis patients: results from the EAGER trial","volume":"48 Suppl 36","author":"Nasr","year":"2013","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1016\/S1569-1993(11)60345-7","article-title":"Validation of the treatment satisfaction questionnaire for medication (TSQM) in cystic fibrosis","volume":"10 Suppl 1","author":"Regnault","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1016\/S1569-1993(11)60336-6","article-title":"Association of treatment satisfaction and compliance of cystic fibrosis (CF) patients using inhaled tobramycin treatment in the EAGER study","volume":"10 Suppl 1","author":"Regnault","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"issue":"6","key":"10.1002\/14651858.CD004197.pub5-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jcf.2012.04.007","article-title":"Validation of the treatment satisfaction questionnaire for medication in patients with cystic fibrosis","volume":"11","author":"Regnault","year":"2012","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0112|cit112","first-page":"317","article-title":"Analysis of long-term liposomal amikacin for inhalation in patients with cystic fibrosis and chronic infection from pseudomonas aeruginosa","volume":"49 Suppl 38","author":"Bilton","year":"2014","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1016\/S1569-1993(15)30289-7","article-title":"Analysis of long-term use of liposomal amikacin for inhalation (LAI) in patients with cystic fibrosis (CF) who have chronic infection from Pseudomonas aeruginosa","volume":"14 Suppl 1","author":"Bilton","year":"2015","journal-title":"Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0114|cit114","first-page":"270, Abstract n","article-title":"Long-term study of liposomal amikacin for inhalation (LAI) in patients with cystic fibrosis (CF) and chronic pseudomonas aeruginosa infection [abstract]","volume":"50 Suppl 41","author":"Konstan","year":"2015","journal-title":"Pediatric Pulmonology"},{"issue":"2","key":"10.1002\/14651858.CD004197.pub5-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jcf.2007.07.001","article-title":"Efficacy and safety of intravenous meropenem and tobramycin versus ceftazidime and tobramycin in cystic fibrosis","volume":"7","author":"Latzin","year":"2008","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2165\/00148581-200709001-00003","article-title":"Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa","volume":"9 Suppl","author":"Lenoir","year":"2007","journal-title":"Paediatric Drugs"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/S1569-1993(06)80166-9","article-title":"Aerosolized tobramycin in the treatment of patients with cystic fibrosis and pseudomonas aeruginosa infection","volume":"5 Suppl 1","author":"Lenoir","year":"2006","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0118|cit118","first-page":"620s","article-title":"Highly concentrated aerosolized tobramycin in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection","volume":"26 Suppl 49","author":"Lenoir","year":"2005","journal-title":"European Respiratory Journal"},{"issue":"8433","key":"10.1002\/14651858.CD004197.pub5-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S0140-6736(85)92222-6","article-title":"Nebulised colomycin for early pseudomonal colonisation in cystic fibrosis [letter]","volume":"1","author":"Littlewood","year":"1985","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"209","DOI":"10.2147\/DDDT.S54064","article-title":"Sinonasal inhalation of tobramycin vibrating aerosol in cystic fibrosis patients with upper airway Pseudomonas aeruginosa colonization: results of a randomized, double-blind, placebo-controlled pilot study","volume":"8","author":"Mainz","year":"2014","journal-title":"Drug Design, Development and Therapy"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S1569-1993(11)60101-X","article-title":"Sinonasal inhalation of tobramycin in cystic fibrosis patients with P. aeruginosa colonization of the upper airways - results of a multicentric placebo-controlled pilot study","volume":"10 Suppl 1","author":"Mainz","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"issue":"2","key":"10.1002\/14651858.CD004197.pub5-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.anl.2010.09.001","article-title":"Sinonasal inhalation of dornase alfa in CF: A double-blind placebo-controlled cross-over pilot trial","volume":"38","author":"Mainz","year":"2011","journal-title":"Auris, Nasus, Larynx"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0123|cit123","first-page":"S28","article-title":"Comparison of two inhaled tobramycin solutions in cystic fibrosis patients with chronic pseudomonas aeruginosa infection: results in different age subgroups","volume":"10 Suppl 1","author":"Mazurek","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1016\/S1569-1993(12)60239-2","article-title":"Efficacy on lung function and safety of multiple courses of tobramycin 300mg\/4 ml nebuliser solution (Bramitob) in patients with cystic fibrosis and chronic pseudomonas aeruginosa infection: results from a 48-week extension phase","volume":"11 Suppl1","author":"Mazurek","year":"2012","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0125|cit125","first-page":"S28","article-title":"Head-to-head comparison of two inhaled tobramycin solutions in cystic fibrosis (CF) patients with chronic pseudomonas aeruginosa (Pa) infection","volume":"10 Suppl 1","author":"Mazurek","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"issue":"S32","key":"10.1002\/14651858.CD004197.pub5-BIB0126|cit126","first-page":"309","article-title":"Antibiotic susceptibility in Pseudomonas Aeruginosa (PA) isolates following exposure to aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis","volume":"44","author":"Oermann","year":"2009","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl 32","key":"10.1002\/14651858.CD004197.pub5-BIB0127|cit127","first-page":"335","article-title":"Effect of repeated exposure to aztreonam for inhalation solution (AZLI) therapy on cystic fibrosis respiratory pathogens","volume":"44","author":"Oermann","year":"2009","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0128|cit128","first-page":"S28","article-title":"Effect of multiple courses of Aztreonam Lysine for inhalation (AZLI) on FEV1 and weight in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa (PA): analysis of 18 month data from CP-AI-006","volume":"8 Suppl 2","author":"Oermann","year":"2009","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0129|cit129","first-page":"S28","article-title":"Adherence over multiple courses of Aztreonam for inhalation (AZLI): effect on disease- related endpoints in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa (PA)","volume":"8 Suppl 2","author":"Oermann","year":"2009","journal-title":"Journal of Cystic Fibrosis"},{"issue":"11","key":"10.1002\/14651858.CD004197.pub5-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/ppul.21301","article-title":"An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis","volume":"45","author":"Oermann","year":"2010","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0131|cit131","first-page":"299","article-title":"Effects of chronic intermittent aztreonam for inhalation solution (AZLI) on health-related quality of life (HRQOL) in persons with cystic fibrosis (CF) and P. aeruginosa","volume":"46 Suppl 34","author":"Quitnner","year":"2011","journal-title":"Pediatric Pulmonology"},{"issue":"8","key":"10.1002\/14651858.CD004197.pub5-BIB0132|cit132","first-page":"25","article-title":"Evaluation of pefloxacin efficacy and tolerability in the treatment and prophylaxis of severe infections at the children with mucoviscidosis and aplastic anaemia","volume":"45","author":"Postnikov","year":"2000","journal-title":"Antibiotiki i Khimioterapiia"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/S1569-1993(07)60126-X","article-title":"A prospective trial on the efficacy and tolerability of twice-daily dosing (TDD) versus once-daily dosing (ODD) amikacin in cystic fibrosis patients","volume":"6 Suppl 1","author":"Postnikov","year":"2007","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0134|cit134","first-page":"299","article-title":"Are morning doses of intravenous tobramycin less nephrotoxic than evening? Evidence from urinary biomarkers in the critic study","volume":"48 Suppl 36","author":"Prayle","year":"2013","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0135|cit135","first-page":"273","article-title":"Economic analysis of hospitalization and home IV anti-pseudomonal antibiotic use in CF patients on tobramycin solution for inhalation (TOBI\u00ae)","volume":"Suppl 17","author":"Birnbaum","year":"1998","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD004197.pub5-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"S194","DOI":"10.1016\/S1569-1993(02)00003-6","article-title":"The long-term use of inhaled tobramycin in patients with cystic fibrosis","volume":"1 Suppl 2","author":"Bowman","year":"2002","journal-title":"Journal of Cystic Fibrosis"},{"issue":"5","key":"10.1002\/14651858.CD004197.pub5-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1086\/314727","article-title":"Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis","volume":"179","author":"Burns","year":"1999","journal-title":"Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0138|cit138","unstructured":"Casey S Ramsey B Borowitz D Nutritional benefits of chronic intermittent Pseudomonas aeruginosa suppression with tobramycin solution for inhalation in adolescents 13th International Cystic Fibrosis Congress; 2000 June 4-8; Stockholm, Sweden 2000 172"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0139|cit139","first-page":"339","article-title":"Mortality rates during 2 years of treatment with intermittent inhaled tobramycin (TOBI) in CF","volume":"Suppl 19","author":"Enger","year":"1999","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl 31","key":"10.1002\/14651858.CD004197.pub5-BIB0141|cit140","first-page":"1545","article-title":"Long term effect of tobramycin solution for inhalation on reduction of hospitalization of CF patients","volume":"16","author":"Fiel","year":"2000","journal-title":"European Respiratory Journal"},{"issue":"Suppl 31","key":"10.1002\/14651858.CD004197.pub5-BIB0140|cit141","first-page":"1545","article-title":"Long term effect of tobramycin solution for inhalation on reduction of hospitalization of CF patients [abstract]","volume":"16","author":"Fiel","year":"2000","journal-title":"European Respiratory Journal"},{"issue":"1","key":"10.1002\/14651858.CD004197.pub5-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1378\/chest.122.1.219","article-title":"Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis","volume":"122","author":"Geller","year":"2002","journal-title":"Chest"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0143|cit143","first-page":"283","article-title":"Epidemiology of Stenotrophomonas maltophilia culture in cystic fibrosis (CF) patients during the tobramycin solution for inhalation (TOBI\u00ae) study","volume":"Suppl 20","author":"Graff","year":"2000","journal-title":"Pediatric Pulmonology"},{"issue":"1","key":"10.1002\/14651858.CD004197.pub5-BIB0144|cit144","first-page":"130","article-title":"Intermittent administration of inhaled tobramycin in patients with cystic fibrosis","volume":"135","author":"Hazinski","year":"1999","journal-title":"Journal of Pediatrics"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0145|cit145","first-page":"305","article-title":"Peripheral white blood cell count as a surrogate marker for progression of lung disease in cystic fibrosis","volume":"Suppl 22","author":"Konstan","year":"2001","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl","key":"10.1002\/14651858.CD004197.pub5-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1016\/S0300-2977(99)90288-7","article-title":"Who benefits more? An age-stratified analysis of lung function and weight gain in CF patients using inhaled tobramycin","volume":"54","author":"Kylstra","year":"1999","journal-title":"Netherlands Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD004197.pub5-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0149-2918(00)87985-0","article-title":"Savings in direct medical costs from the use of tobramycin solution for inhalation in patients with cystic fibrosis","volume":"22","author":"LeLorier","year":"2000","journal-title":"Clinical Therapeutics"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD004197.pub5-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"118S","DOI":"10.1378\/chest.120.3_suppl.118S","article-title":"Microbiological and immunologic considerations with aerosolized drug delivery","volume":"120","author":"LiPuma","year":"2001","journal-title":"Chest"},{"issue":"3","key":"10.1002\/14651858.CD004197.pub5-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1086\/315312","article-title":"Aminoglycoside-resistance mechanisms for cystic fibrosis Pseudomonas aeruginosa isolates are unchanged by long-term, intermittent, inhaled tobramycin treatment","volume":"181","author":"MacLeod","year":"2000","journal-title":"Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0150|cit150","first-page":"243","article-title":"Who benefits more? An analysis of FEV1 and weight in adolescent (age 13-<18) CF patients using inhaled tobramycin (TOBI)","volume":"Suppl 19","author":"Moss","year":"1999","journal-title":"Pediatric Pulmonology"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD004197.pub5-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"107S","DOI":"10.1378\/chest.120.3_suppl.107S","article-title":"Administration of aerosolized antibiotics in cystic fibrosis patients","volume":"120","author":"Moss","year":"2001","journal-title":"Chest"},{"issue":"1","key":"10.1002\/14651858.CD004197.pub5-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1378\/chest.121.1.55","article-title":"Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis","volume":"121","author":"Moss","year":"2002","journal-title":"Chest"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0153|cit153","first-page":"243","article-title":"Safety and effectiveness of 2 years of treatment with intermittent inhaled tobramycin in CF patients","volume":"Suppl 19","author":"Nickerson","year":"1999","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0154|cit154","first-page":"273","article-title":"Seasonality of hospitalization for pulmonary exacerbations and lower respiratory tract infections in Phase III tobramycin solution for inhalation (TOBI\u00ae) trials","volume":"Suppl 17","author":"Otto","year":"1998","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl","key":"10.1002\/14651858.CD004197.pub5-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/S0300-2977(99)90290-5","article-title":"Treatment for exacerbation only does not arrest progressive lung function decline in CF","volume":"54","author":"Quan","year":"1999","journal-title":"Netherlands Journal of Medicine"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0156|cit156","unstructured":"Quittner A Gordon D Yu X Convergence of quality of life assessments and clinical outcomes in patients enrolled in the tobramycin solution for inhalation (TSI) trials 24th European Cystic Fibrosis Conference; 2001 June 6-9; Vienna, Austria 2001 P326"},{"issue":"4","key":"10.1002\/14651858.CD004197.pub5-BIB0158|cit157","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/ppul.10074","article-title":"Effects of tobramycin solution for inhalation on global ratings of quality of life in patients with cystic fibrosis and Pseudomonas aeruginosa infection","volume":"33","author":"Quittner","year":"2002","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0157|cit158","first-page":"349","article-title":"Longitudinal changes in global ratings of quality of life for patients in the tobramycin solution for inhalation (TSI) trials","volume":"Suppl 22","author":"Quittner","year":"2001","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0159|cit159","first-page":"137","article-title":"Safety and efficacy of Tobramycin Solution for Inhalation in patients with cystic fibrosis: The results of two phase III placebo controlled clinical trials","volume":"Suppl 14","author":"Ramsey","year":"1997","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0160|cit160","unstructured":"Ramsey BW Bowman MC Montgomery AB Smith AR TOBIStudy G Design of phase 3 aerosolized tobramycin studies for chronic intermittent therapy 21st European Cystic Fibrosis Conference; 1997 June 1-6; Davos, Switzerland 1997 144"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0161|cit161","unstructured":"Ramsey BW Bowman MC Vasiljev-KM Smith AR TOBIStudy G Results of phase 3 aerosolized tobramycin studies for chronic intermittent therapy [abstract] 21st European Cystic Fibrosis Conference; 1997 June 1-6; Davos, Switzerland 1997 144"},{"issue":"1","key":"10.1002\/14651858.CD004197.pub5-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJM199901073400104","article-title":"Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. cystic fibrosis Inhaled Tobramycin Study Group","volume":"340","author":"Ramsey","year":"1999","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD004197.pub5-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1067\/mpd.2001.117288","article-title":"Defining a pulmonary exacerbation in cystic fibrosis","volume":"139","author":"Rosenfeld","year":"2001","journal-title":"Journal of Pediatrics"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0164|cit164","first-page":"291","article-title":"Nebulised high dose Tobramycin (TOBI) in adolescents with cystic fibrosis","volume":"Suppl 22","author":"Taylor","year":"2001","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0165|cit165","first-page":"298","article-title":"Effect of tobramycin solution for inhalation (TOBI\u00ae) on long term rates of lung function decline in Pseudomonas aeruginosa infected cystic fibrosis (CF) patients with mild to moderate lung disease","volume":"Suppl 20","author":"VanDevanter","year":"2000","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0166|cit166","unstructured":"VanDevanter D Yu X Konstan MW Effect of tobramycin solution for inhalation on circulating white blood cell counts in exacerbating and stable CF patients 24th European Cystic Fibrosis Conference; 2001 June 6-9; Vienna, Austria 2001 P172"},{"issue":"9286","key":"10.1002\/14651858.CD004197.pub5-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(01)06124-4","article-title":"Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis","volume":"358","author":"Ratjen","year":"2001","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0168|cit168","first-page":"S55","article-title":"Microbiology results from a phase 2 clinical study of aztreonam lysinate for inhalation (AI): a new inhaled antibiotic to treat CF patients with Pseudomonas aeruginosa (PA)","volume":"4 Suppl","author":"Burns","year":"2005","journal-title":"Journal of Cystic Fibrosis"},{"issue":"1","key":"10.1002\/14651858.CD004197.pub5-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/ppul.20736","article-title":"A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection","volume":"43","author":"Retsch-Bogart","year":"2008","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0170|cit170","unstructured":"Retsch-Bogart GZ Gibson RL AIPhase 2SG A phase 2 study of aztreonam lysinate for inhalation to treat cystic fibrosis patients with Pseudomonas aeruginosa infection American Thoracic Society International Conference; 2005 May 20-25; San Diego, USA 2005 A576"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0171|cit171","first-page":"320","article-title":"Sustained improvement in pulmonary function following a 28-day course of 75mg azli tid therapy","volume":"43 Suppl 31","author":"Retsch-Bogart","year":"2008","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0172|cit172","first-page":"341","article-title":"Investigation of susceptibility breakpoints for inhaled antibiotic therapies in cystic fibrosis","volume":"45 Suppl 33","author":"McCoy","year":"2010","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/S1569-1993(09)60112-0","article-title":"Efficacy of Aztreonam Lysine for inhalation (AZLI) in patients with cystic fibrosis and drug resistant P. aeruginosa (DRPA)","volume":"8 Suppl 2","author":"McCoy","year":"2009","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0174|cit174","first-page":"351","article-title":"Relevance of established susceptibility breakpoints to clinical efficacy of inhaled antibiotic therapies in cystic fibrosis","volume":"43 Suppl 31","author":"McCoy","year":"2008","journal-title":"Pediatric Pulmonology"},{"issue":"14","key":"10.1002\/14651858.CD004197.pub5-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.2165\/10484070-000000000-00000","article-title":"Aztreonam lysine for inhalation solution: in cystic fibrosis","volume":"70","author":"Plosker","year":"2010","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0176|cit176","first-page":"299","article-title":"Effects of chronic intermittent aztreonam for inhalation solution (AZLI) on health-related quality of life (HRQOL) in persons with cystic fibrosis (CF) and P. aeruginosa","volume":"46 Suppl 34","author":"Quittner","year":"2011","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0177|cit177","first-page":"305","article-title":"Effect of a 28-day course of aztreonam for inhalation solution (AZLI) on responses to individual CFQ-R respiratory symptoms score questions among patients with CF","volume":"44 Suppl 32","author":"Quittner","year":"2009","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0178|cit178","first-page":"320","article-title":"Source of improvements in lung function in patients with cystic fibrosis (CF) following treatment with aztreonam lysine for inhalation (AZLI)","volume":"43 Suppl 31","author":"Retsch-Bogart","year":"2008","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0179|cit179","first-page":"320","article-title":"Sustained improvement in pulmonary function following a 28-day course of 75mg azli tid therapy","volume":"43 Suppl 31","author":"Retsch-Bogart","year":"2008","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0180|cit180","first-page":"310","article-title":"Phase 3 trial (AIR-CF 1) measuring improvement in respiratory symptoms in patients with cystic fibrosis (CF) following treatment with aztreonam lysine for inhalation","volume":"42 Suppl 30","author":"Retsch-Bogart","year":"2007","journal-title":"Pediatric Pulmonology"},{"issue":"5","key":"10.1002\/14651858.CD004197.pub5-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1378\/chest.08-1421","article-title":"Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis","volume":"135","author":"Retsch-Bogart","year":"2009","journal-title":"Chest"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/S1569-1993(09)60110-7","article-title":"Pharmacokinetics of tobramycin (TOBI) after 4 and 8 weeks of continuous once daily or twice daily inhalation","volume":"8 Suppl 2","author":"Rietschel","year":"2009","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0183|cit183","first-page":"320","article-title":"Pharmacokinetics of continuous treatment with O.D. or B.I.D inhalation of tobramycin (TOBI\u2122) via Pari Eflow\u2122 Rapid","volume":"45 Suppl 33","author":"Rietschel","year":"2010","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/S1569-1993(10)60086-0","article-title":"Pharmacokinetics of continuous treatment with o.d. or b.i.d. inhalation of tobramycin (TOBITM)","volume":"9 Suppl 1","author":"Rietschel","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"issue":"2","key":"10.1002\/14651858.CD004197.pub5-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1089\/jamp.2011.0942","article-title":"Sputum tobramycin concentrations in cystic fibrosis patients with repeated administration of inhaled tobramycin","volume":"26","author":"Ruddy","year":"2013","journal-title":"Journal of Aerosol Medicine and Pulmonary Drug Delivery"},{"issue":"1","key":"10.1002\/14651858.CD004197.pub5-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/00006454-199701000-00032","article-title":"Ciprofloxacin as antipseudomonal treatment in patients with cystic fibrosis","volume":"16","author":"Schaad","year":"1997","journal-title":"Pediatric Infectious Diseases Journal"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/S1569-1993(09)60156-9","article-title":"Genotype based evaluation of eradication treatment of new P. aeruginosa infections in CF patients","volume":"8 Suppl 2","author":"Schelstraete","year":"2009","journal-title":"Journal of Cystic Fibrosis"},{"issue":"2","key":"10.1002\/14651858.CD004197.pub5-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jcf.2009.11.006","article-title":"Genotype based evaluation of Pseudomonas aeruginosa eradication treatment success in cystic fibrosis patients","volume":"9","author":"Schelstraete","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/S1569-1993(12)60038-1","article-title":"A randomised, open label phase 3 study to evaluate the efficacy and safety of a dry powder formulation of inhaled colistimethate sodium (Colobreathe\u00ae) versus tobramycin nebuliser solution (TNS) in cystic fibrosis subjects with chronic Pseudomonas aeruginosa lung infection","volume":"11, Suppl 1","author":"Goldman","year":"2012","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0190|cit190","first-page":"331","article-title":"Lack of emergence of antimicrobial resistance of Pseudomonas Aeruginosa after six months inhalation of dry powder colistimethate","volume":"43 Suppl 31","author":"Goldman","year":"2008","journal-title":"Pediatric Pulmonology"},{"issue":"S35","key":"10.1002\/14651858.CD004197.pub5-BIB0191|cit191","first-page":"353","article-title":"A randomised, open label phase 3 study to evaluate the efficacy and safety of a dry powder formulation of colistimethate sodium (Colobreathe\u00ae) versus tobramycin nebuliser solution (TNS) in cystic fibrosis subjects with chronic Pseudomonas aeruginosa lung infection","volume":"47","author":"Goldman","year":"2012","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0192|cit192","first-page":"347","article-title":"Does persistence with inhaled dry powder antibiotic treatment improve tolerability?","volume":"48 Suppl 36","author":"Goldman","year":"2013","journal-title":"Pediatric Pulmonology"},{"issue":"4","key":"10.1002\/14651858.CD004197.pub5-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"344-350 Online","DOI":"10.1136\/thoraxjnl-2012-202059","article-title":"Online Data Supplement to 'Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised' [online] study","volume":"68","author":"Schuster","year":"2013","journal-title":"Thorax"},{"issue":"4","key":"10.1002\/14651858.CD004197.pub5-BIB0194|cit194","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1136\/thoraxjnl-2012-202059","article-title":"Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study","volume":"68","author":"Schuster","year":"2013","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/S1569-1993(15)30295-2","article-title":"Efficacy and safety of colistimethate sodium in a paediatric population: results from the FREEDOM trial","volume":"14 Suppl 1","author":"Schuster","year":"2015","journal-title":"Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society"},{"issue":"2","key":"10.1002\/14651858.CD004197.pub5-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1089\/jamp.2013.1056","article-title":"Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a Phase I, randomized, single-dose, dose-escalation study","volume":"28","author":"Stass","year":"2015","journal-title":"Journal of Aerosol Medicine and Pulmonary Drug Delivery"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0197|cit197","first-page":"300","article-title":"Safety and pharmacokinetics of inhaled dry powder ciprofloxacin after single and multiple inhalations in patients with cystic fibrosis","volume":"43 Suppl 31","author":"Stass","year":"2008","journal-title":"Paediatric Pulmomology"},{"issue":"10","key":"10.1002\/14651858.CD004197.pub5-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.clinthera.2013.08.003","article-title":"Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study","volume":"35","author":"Stass","year":"2013","journal-title":"Clinical Therapeutics"},{"issue":"7","key":"10.1002\/14651858.CD004197.pub5-BIB0199|cit199","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1136\/adc.64.7.1022","article-title":"Treatment of Pseudomonas aeruginosa colonisation in cystic fibrosis","volume":"64","author":"Steinkamp","year":"1989","journal-title":"Archives of Disease in Childhood"},{"issue":"S30","key":"10.1002\/14651858.CD004197.pub5-BIB0200|cit200","first-page":"300","article-title":"Once weekly azithromycin in cystic fibrosis: a double-blind, randomised trial in patients with chronic Pseudomonas aeruginosa infection","volume":"42","author":"Steinkamp","year":"2007","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/S1569-1993(06)80098-6","article-title":"Clinical and immunomodulatory effects of once weekly azithromycin treatment in cystic fibrosis patients chronically infected with Pseudomonas aeruginosa","volume":"5 Suppl 1","author":"Steinkamp","year":"2006","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0202|cit202","first-page":"315","article-title":"A phase 1 safety, tolerability and pharmacokinetic (PK) study of MP-376 (levofloxacin solution for inhalation) in stable cystic fibrosis (CF) patients","volume":"43 Suppl 31","author":"Geller","year":"2008","journal-title":"Paediatric Pulmonology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD004197.pub5-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/S1569-1993(08)60101-0","article-title":"Single-dose pharmacokinetics of aerosol MP-376 (levofloxacin solution for inhalation) in cystic fibrosis patients: PK-PD implications","volume":"7","author":"Griffith","year":"2008","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"S23, Abstract n","DOI":"10.1016\/S1569-1993(11)60106-9","article-title":"Levofloxacin pharmacokinetics (PK) after administration of MP-376 (Levofloxacin inhalation solution; Aeroquin) in children with cystic fibrosis [abstract]","volume":"10 Suppl 1","author":"Kearns","year":"2011","journal-title":"Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society"},{"issue":"1","key":"10.1002\/14651858.CD004197.pub5-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1586\/17476348.2015.986469","article-title":"Levofloxacin inhalation solution for the treatment of chronic Pseudomonas aeruginosa infection among patients with cystic fibrosis","volume":"9","author":"Stockmann","year":"2015","journal-title":"Expert Review of Respiratory Medicine"},{"issue":"3","key":"10.1002\/14651858.CD004197.pub5-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1183\/09031936.05.00009605","article-title":"Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients","volume":"26","author":"Taccetti","year":"2005","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0207|cit207","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/S1569-1993(09)60148-X","article-title":"Prevention of initial P. aeruginosa infection in children with cystic fibrosis: a multi-centre double-blind randomised controlled trial","volume":"8 Suppl 2","author":"Tramper-Stranders","year":"2009","journal-title":"Journal of Cystic Fibrosis"},{"issue":"10","key":"10.1002\/14651858.CD004197.pub5-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1136\/thx.2009.126128","article-title":"Controlled trial of cycled antibiotic prophylaxis to prevent initial Pseudomonas aeruginosa infection in children with cystic fibrosis","volume":"65","author":"Tramper-Stranders","year":"2010","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0209|cit209","first-page":"338, Abstract n","article-title":"Fosfomycin\/tobramycin for inhalation (FTI): microbiological results of a phase 2 placebo-controlled trial in patients with cystic fibrosis and pseudomonas aeruginosa [abstract]","volume":"45 Suppl 33","author":"McColley","year":"2010","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0210|cit210","first-page":"302","article-title":"Fosfomycin\/tobramycin for inhalation FTI): safety results of a phase 2 placebo-controlled trial in patients with cystic fibrosis and pseudomonas aeruginosa","volume":"45 Suppl 33","author":"Trapnell","year":"2010","journal-title":"Pediatric Pulmonology"},{"issue":"2","key":"10.1002\/14651858.CD004197.pub5-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1164\/rccm.201105-0924OC","article-title":"Fosfomycin\/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection","volume":"185","author":"Trapnell","year":"2012","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0212|cit212","first-page":"302","article-title":"Fosfomycon\/tobramycin for inhalation (FTI): efficacy results of a phase 2 placebo-controlled trial in patients with cystic fibrosis and pseudomonas aeruginosa","volume":"45 Suppl 33","author":"Trapnell","year":"2010","journal-title":"Pediatric Pulmonology"},{"issue":"3","key":"10.1002\/14651858.CD004197.pub5-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1651-2227.1993.tb12668.x","article-title":"Early treatment of Pseudomonas aeruginosa colonisation in cystic fibrosis","volume":"82","author":"Vazquez","year":"1993","journal-title":"Acta Paediatrica Scandanavia"},{"issue":"7","key":"10.1002\/14651858.CD004197.pub5-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1136\/thoraxjnl-2012-202342","article-title":"Prospective evaluation of respiratory exacerbations in children with cystic fibrosis from newborn screening to 5 years of age","volume":"68","author":"Byrnes","year":"2013","journal-title":"Thorax"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD004197.pub5-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/S1569-1993(09)60157-0","article-title":"Interim outcomes of a Pseudomonas aeruginosa (Pa) eradication protocol in young children in the Australian Cystic Fibrosis Bronchoalveolar Lavage (ACFBAL) Study","volume":"8","author":"Cheney","year":"2009","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1016\/S1569-1993(10)60452-3","article-title":"Trials, tribulations and triumphs of a cystic fibrosis study - a behind the scenes look at the workings of an international multi-centre study","volume":"9 Suppl 1","author":"Cheney","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"issue":"3","key":"10.1002\/14651858.CD004197.pub5-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jcf.2014.12.007","article-title":"Pseudomonas aeruginosa genotypes acquired by children with cystic fibrosis by age 5-years","volume":"14","author":"Kidd","year":"2015","journal-title":"Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society"},{"issue":"3","key":"10.1002\/14651858.CD004197.pub5-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jpeds.2014.05.031","article-title":"Costs of bronchoalveolar lavage-directed therapy in the first 5 years of life for children with cystic fibrosis","volume":"165","author":"Moodie","year":"2014","journal-title":"Journal of Pediatrics"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0219|cit219","first-page":"317","article-title":"Australasian cystic fibrosis BAL study interim analysis","volume":"41 Suppl 29","author":"Wainwright","year":"2006","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0221|cit220","first-page":"300","article-title":"Early infection with pseudomonas aeruginosa can be cleared in young children with cystic fibrosis","volume":"34 Suppl 24","author":"Wainwright","year":"2002","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0222|cit221","first-page":"320","article-title":"Australasian CF bronchoalveolar lavage (ACFBAL) study: P.Aeruginosa (PA) genotypes in pre-school CF children","volume":"46 Suppl 34","author":"Wainwright","year":"2011","journal-title":"Pediatric Pulmonology"},{"issue":"2","key":"10.1002\/14651858.CD004197.pub5-BIB0223|cit222","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1001\/jama.2011.954","article-title":"Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: a randomized trial","volume":"306","author":"Wainwright","year":"2011","journal-title":"JAMA"},{"issue":"2","key":"10.1002\/14651858.CD004197.pub5-BIB0224|cit223","doi-asserted-by":"crossref","first-page":"163-171 Online","DOI":"10.1001\/jama.2011.954","article-title":"Online Supplement to 'Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: a randomized trial' [online]","volume":"306","author":"Wainwright","year":"2011","journal-title":"JAMA"},{"issue":"10","key":"10.1002\/14651858.CD004197.pub5-BIB0220|cit224","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/ppul.20885","article-title":"Safety\u00a0of\u00a0bronchoalveolar lavage\u00a0in\u00a0young children\u00a0with cystic fibrosis","volume":"43","author":"Wainwright","year":"2008","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0225|cit225","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/S1569-1993(10)60082-3","article-title":"A double-blind, multinational, randomized, placebo-controlled trial evaluating aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis (CF), mild lung disease and P. aeruginosa","volume":"9 Suppl 1","author":"Wainwright","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"issue":"4","key":"10.1002\/14651858.CD004197.pub5-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jcf.2011.02.007","article-title":"Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa","volume":"10","author":"Wainwright","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"issue":"S30","key":"10.1002\/14651858.CD004197.pub5-BIB0227|cit227","first-page":"332","article-title":"Comparison of antibiotics for early pseudomonas infection in CF: interim data analysis","volume":"42","author":"Noah","year":"2007","journal-title":"Pediatric Pulmonology"},{"issue":"3","key":"10.1002\/14651858.CD004197.pub5-BIB0228|cit228","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/ppul.21176","article-title":"Inhaled versus systemic antibiotics and airway inflammation in children with cystic fibrosis and Pseudomonas","volume":"45","author":"Noah","year":"2010","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0229|cit229","article-title":"TOBI\u00ae for eradication of early P. aeruginosa infection in paediatric cystic fibrosis patients: the EARLY study","volume":"15 Suppl 1","author":"Ratjen","year":"2016","journal-title":"Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0230|cit230","unstructured":"Langton Hewer S TORPEDO-CF http:\/\/www.controlled-trials.com\/ISRCTN02734162\/torpedo-cf"},{"issue":"2","key":"10.1002\/14651858.CD004197.pub5-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0022-3476(05)80729-2","article-title":"Early bacteriologic, immunologic and clinical courses of young infants with cystic fibrosis identified by neonatal screening","volume":"119","author":"Abman","year":"1991","journal-title":"Journal of Pediatrics"},{"issue":"2","key":"10.1002\/14651858.CD004197.pub5-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jcf.2012.08.001","article-title":"Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial","volume":"12","author":"Anstead","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"issue":"5","key":"10.1002\/14651858.CD004197.pub5-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/(SICI)1099-0496(199605)21:5<267::AID-PPUL1>3.0.CO;2-K","article-title":"Bronchoalveolar lavage or oropharyngeal cultures to identify lower respiratory pathogens in infants with cystic fibrosis","volume":"21","author":"Armstrong","year":"1996","journal-title":"Pediatric Pulmonology"},{"issue":"3","key":"10.1002\/14651858.CD004197.pub5-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1086\/318075","article-title":"Longitudanal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis","volume":"183","author":"Burns","year":"2001","journal-title":"Journal of Infectious Diseases"},{"issue":"2","key":"10.1002\/14651858.CD004197.pub5-BIB0235|cit235","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1574-695X.2012.00983.x","article-title":"Phenotypes selected during chronic lung infection in cystic fibrosis patients: implications for the treatment of Pseudomonas aeruginosa biofilm infections","volume":"65","author":"Ciofu","year":"2012","journal-title":"FEMS Immunology and Medical Microbiology"},{"issue":"2","key":"10.1002\/14651858.CD004197.pub5-BIB0236|cit236","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1183\/09031936.00043108","article-title":"Acquisition and eradication of P. aeruginosa in young children with cystic fibrosis","volume":"33","author":"Douglas","year":"2009","journal-title":"European Respiratory Journal"},{"issue":"4","key":"10.1002\/14651858.CD004197.pub5-BIB0237|cit237","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1034\/j.1399-3003.2000.16d30.x","article-title":"Antibiotic therapy against Pseudomonas aeruginosa: a European consensus","volume":"16","author":"D\u00f6ring","year":"2000","journal-title":"European Respiratory Journal"},{"issue":"6","key":"10.1002\/14651858.CD004197.pub5-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jcf.2012.10.004","article-title":"Treatment of lung infection in patients with cystic fibrosis: Current and future strategies","volume":"11","author":"D\u00f6ring","year":"2012","journal-title":"Journal of Cystic Fibrosis"},{"issue":"2","key":"10.1002\/14651858.CD004197.pub5-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ppul.10127","article-title":"Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis","volume":"34","author":"Emerson","year":"2002","journal-title":"Pediatric Pulmonology"},{"issue":"1","key":"10.1002\/14651858.CD004197.pub5-BIB0240|cit240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-3476(05)83478-X","article-title":"The changing epidemiology of cystic fibrosis","volume":"122","author":"FitzSimmons","year":"1993","journal-title":"Journal of Pediatrics"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0241|cit241","first-page":"267","article-title":"The Cystic Fibrosis Foundation Patient Registry Report 1996","volume":"Suppl 21","author":"Fitzsimmons","year":"1996","journal-title":"Pediatric Pulmonology"},{"issue":"7414","key":"10.1002\/14651858.CD004197.pub5-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0243|cit243","unstructured":"Higgins JPT Altman DG Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"10","key":"10.1002\/14651858.CD004197.pub5-BIB0244|cit244","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1136\/adc.2006.105825","article-title":"Bronchoscopy following diagnosis with cystic fibrosis","volume":"92","author":"Hilliard","year":"2007","journal-title":"Archives of Disease in Childhood"},{"issue":"6","key":"10.1002\/14651858.CD004197.pub5-BIB0245|cit245","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0022-3476(09)90007-5","article-title":"Prognostic implications of initial oropharyngeal bacterial flora in patients with cystic fibrosis diagnosed before the age of two years","volume":"122","author":"Hudson","year":"1993","journal-title":"Journal of Pediatrics"},{"issue":"3","key":"10.1002\/14651858.CD004197.pub5-BIB0246|cit246","first-page":"115","article-title":"Respiratory Tract Bacteriology in Cystic Fibrosis","volume":"106","author":"Iacocca","year":"1963","journal-title":"American Journal of Disease in Childhood"},{"issue":"8","key":"10.1002\/14651858.CD004197.pub5-BIB0247|cit247","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001399.pub4","article-title":"Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis","author":"Johansen","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD004197.pub5-BIB0248|cit248","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/00006454-199007000-00008","article-title":"Risk factors for Pseudomonas aeruginosa colonisation in cystic fibrosis patients","volume":"9","author":"Kerem","year":"1990","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"4","key":"10.1002\/14651858.CD004197.pub5-BIB0249|cit249","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ppul.2009.abs","article-title":"Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition","volume":"32","author":"Kosorok","year":"2001","journal-title":"Pediatric Pulmonology"},{"issue":"1","key":"10.1002\/14651858.CD004197.pub5-BIB0250|cit250","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1569-1993(02)00141-8","article-title":"Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients","volume":"2","author":"Lee","year":"2003","journal-title":"Journal of Cystic Fibrosis"},{"issue":"2","key":"10.1002\/14651858.CD004197.pub5-BIB0251|cit251","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/ppul.10401","article-title":"Reduction in prevalence of chronic Pseudomonas aeruginosa infection at a regional pediatric cystic fibrosis center","volume":"37","author":"Lee","year":"2004","journal-title":"Pediatric Pulmonology"},{"issue":"2","key":"10.1002\/14651858.CD004197.pub5-BIB0252|cit252","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1177\/1479972309104661","article-title":"Eradication of early Pseudomonas infection in cystic fibrosis","volume":"6","author":"Lee","year":"2009","journal-title":"Chronic Respiratory Disease"},{"issue":"17","key":"10.1002\/14651858.CD004197.pub5-BIB0253|cit253","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1001\/jama.294.17.2203","article-title":"Randomized Trials Stopped Early for Benefit: A Systematic Review","volume":"294","author":"Montori","year":"2005","journal-title":"JAMA"},{"issue":"1","key":"10.1002\/14651858.CD004197.pub5-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1164\/ajrccm.160.1.9808096","article-title":"Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients","volume":"160","author":"Muhlebach","year":"1999","journal-title":"American Journal of Respiratory & Critical Care Medicine"},{"issue":"4","key":"10.1002\/14651858.CD004197.pub5-BIB0255|cit255","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/ppul.1121","article-title":"Genotypic characterisation of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonisation","volume":"32","author":"Munck","year":"2001","journal-title":"Pediatric Pulmonology"},{"issue":"5","key":"10.1002\/14651858.CD004197.pub5-BIB0256|cit256","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1067\/mpd.2001.112897","article-title":"Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis","volume":"138","author":"Nixon","year":"2001","journal-title":"Journal of Pediatrics"},{"issue":"1","key":"10.1002\/14651858.CD004197.pub5-BIB0257|cit257","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/ppul.1950190103","article-title":"Effects of Pseudomonas aeruginosa colonisation on lung function and anthropomorphic variables in children with cystic fibrosis","volume":"19","author":"Pamukcu","year":"1995","journal-title":"Pediatric Pulmonology"},{"issue":"9","key":"10.1002\/14651858.CD004197.pub5-BIB0258|cit258","doi-asserted-by":"crossref","first-page":"4744","DOI":"10.1128\/IAI.67.9.4744-4750.1999","article-title":"Pulmonary outcome in cystic fibrosis is influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype","volume":"67","author":"Parad","year":"1999","journal-title":"Infection & Immunity"},{"issue":"3","key":"10.1002\/14651858.CD004197.pub5-BIB0259|cit259","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1056\/NEJM199607183350307","article-title":"Drug therapy: Management of pulmonary disease in patients with cystic fibrosis","volume":"335","author":"Ramsey","year":"1996","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD004197.pub5-BIB0260|cit260","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/1099-0496(200101)31:1<13::AID-PPUL1001>3.0.CO;2-N","article-title":"Effect of continuous antistaphylococcal therapy on the rate of P.aeruginosa acquisition in patients with cystic fibrosis","volume":"31","author":"Ratjen","year":"2001","journal-title":"Pediatric Pulmonology"},{"issue":"5","key":"10.1002\/14651858.CD004197.pub5-BIB0261|cit261","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/(SICI)1099-0496(199911)28:5<321::AID-PPUL3>3.0.CO;2-V","article-title":"Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis","volume":"28","author":"Rosenfeld","year":"1999","journal-title":"Pediatric Pulmonology"},{"issue":"5","key":"10.1002\/14651858.CD004197.pub5-BIB0262|cit262","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/ppul.1144","article-title":"Early pulmonary infection, inflammation and clinical outcomes in infants with cystic fibrosis","volume":"32","author":"Rosenfeld","year":"2001","journal-title":"Pediatric Pulmonology"},{"issue":"5","key":"10.1002\/14651858.CD004197.pub5-BIB0263|cit263","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in randomised controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"issue":"Supplement 1","key":"10.1002\/14651858.CD004197.pub5-BIB0264|cit264","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/j.jcf.2014.03.010","article-title":"European Cystic Fibrosis Society Standards of Care: Best Practice Guidelines","volume":"13","author":"Smyth","year":"2014","journal-title":"Journal of Cystic Fibrosis"},{"issue":"4","key":"10.1002\/14651858.CD004197.pub5-BIB0265|cit265","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001912.pub4","article-title":"Prophylactic anti-staphylococcal antibiotics for cystic fibrosis","author":"Smyth","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD004197.pub5-BIB0266|cit266","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1067\/mpd.2002.121930","article-title":"Antibiotic prophylaxis in infants and young children with cystic fibrosis: a randomised controlled trial","volume":"140","author":"Stutman","year":"2002","journal-title":"Journal of Pediatrics"},{"issue":"3","key":"10.1002\/14651858.CD004197.pub5-BIB0267|cit267","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0022-3476(84)81094-X","article-title":"Cultures of thoracotomy specimens confirm usefulness of sputum cultures in cystic fibrosis","volume":"104","author":"Thomassen","year":"1984","journal-title":"Journal of Pediatrics"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0268|cit268","volume-title":"Cystic Fibrosis Trust Patient Registry User\u2019s Guide","author":"UK CF","year":"2012"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0269|cit269","volume-title":"UK CF Registry: Annual Data Report 2015","author":"UK Cystic Fibrosis","year":"2016"},{"key":"10.1002\/14651858.CD004197.pub5-BIB0270|cit270","unstructured":"UK CF Trust Control of Infection Group Pseudomonas aeruginosa infection in people with cystic fibrosis: suggestions for prevention and control (2nd edition) UK CF Trust 2004"},{"issue":"2","key":"10.1002\/14651858.CD004197.pub5-BIB0271|cit271","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/ppul.1950100210","article-title":"Respiratory tract colonisation with Pseudomonas aeruginosa in cystic fibrosis: correlations between anti-Pseudomonas aeruginosa antibody levels and pulmonary function","volume":"10","author":"Winnie","year":"1991","journal-title":"Pediatric Pulmonology"},{"issue":"4","key":"10.1002\/14651858.CD004197.pub5-BIB0272|cit272","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004197.pub3","article-title":"Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis","author":"Langton-Hewer","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD004197.pub5-BIB0273|cit273","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004197.pub4","article-title":"Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis","author":"Langton-Hewer","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD004197.pub5-BIB0274|cit274","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004197","article-title":"Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis","author":"Wood","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD004197.pub5-BIB0275|cit275","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004197.pub2","article-title":"Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis","author":"Wood","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd004197.pub6","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T00:00:00Z","timestamp":1685664000000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD004197.pub5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T13:06:15Z","timestamp":1641301575000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD004197.pub5"}},"subtitle":[],"editor":[{"name":"Cochrane Cystic Fibrosis and Genetic Disorders Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,4,25]]},"references-count":275,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,2]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd004197.pub5","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD004197.pub6","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,25]]}}}